Synthesis and assessment of formamidines as new histamine H2-receptor antagonists.
Four series of compounds whose substructure contains a formamidine functionalized as a novel group in the chemistry of histamine H2-receptors have been synthesized. Series design, synthesis and pharmacological data including inhibition of histamine-stimulated acid secretion, inhibition of acid secretion p.o. and pA2 are reported. N-[(E)-[[2-[[[2](Diaminomethylene)amino]-4-thiazolyl] methyl]thio]ethyl]amino]methylene]-4-bromo-benzenesulfonamide (ebrotidine, CAS 100981-43-9, FI-3542) was selected for further research.
Anglada
L
L
Centro de Investigación Farmacéutica Grupo Ferrer, Barcelona, Spain.
Raga
M
M
Márquez
M
M
Sacristán
A
A
Castelló
J M
JM
Ortiz
J A
JA
D000578:Amidines / Q000138:chemical synthesis* / Q000494:pharmacology; D000818:Animals; D003864:Depression, Chemical; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship
D000578:Amidines; D006635:Histamine H2 Antagonists; C077922:formamidine